TipRanks (Fri, 23-Jan 8:22 AM ET)
Globe Newswire (Mon, 12-Jan 7:30 AM ET)
Market Chameleon (Tue, 6-Jan 6:44 AM ET)
Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
Globe Newswire (Mon, 5-Jan 8:30 AM ET)
Wave Life Sciences’ $350 Million Upsized Offering Highlights Expanding Investor Demand
Market Chameleon (Wed, 10-Dec 2:08 AM ET)
Globe Newswire (Tue, 9-Dec 9:50 PM ET)
Market Chameleon (Tue, 9-Dec 5:33 AM ET)
Globe Newswire (Mon, 8-Dec 4:01 PM ET)
Turnarounds and 18,000% Growth
Globe Newswire (Mon, 8-Dec 9:43 AM ET)
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Wave Life Sciences Ltd. - trades on the NASDAQ stock market under the symbol WVE.
As of January 27, 2026, WVE stock price climbed to $13.36 with 3,429,293 million shares trading.
WVE has a beta of 1.63, meaning it tends to be more sensitive to market movements. WVE has a correlation of 0.06 to the broad based SPY ETF.
WVE has a market cap of $2.48 billion. This is considered a Mid Cap stock.
Last quarter Wave Life Sciences Ltd. - reported $8 million in Revenue and -$.32 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.02.
In the last 3 years, WVE traded as high as $21.73 and as low as $3.15.
The top ETF exchange traded funds that WVE belongs to (by Net Assets): IWM, VXF, IBB, IWO, VTWO.
WVE has underperformed the market in the last year with a price return of +11.2% while the SPY ETF gained +15.6%. However, in the short term, WVE had mixed performance relative to the market. It has outperformed in the last 3 months, returning +87.4% vs +3.0% return in SPY. But in the last 2 weeks, WVE shares have been beat by the market, returning -4.0% compared to an SPY return of 0.0%.
WVE support price is $12.57 and resistance is $13.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that WVE shares will trade within this expected range on the day.